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Dahl et al. (2016) acknowledged the extended body of research
conducted over the last 18 years since clevidipine was approved as an
investigational new drug, and its importance in gaining a better
understanding of its mechanism of action (Dahl et al., 2016). Their
work focused on testing the hypothesis that speciﬁc CACNA1C splice
variants are encoding for Cav1.2 in lung tissue with a differentRecently, EBioMedicine published a study proposing that
clevidipine's complexmechanism of action might be responsible for re-
lieving dyspnea in acute heart failure (AHF) patients Dahl et al. (2016).
Clevidipine was approved by Food and Drug Administration (FDA)
(2008) as a third generation dihydropyridine (DHP) calcium channel
blocker for the management of perioperative acute hypertension
(Merry et al., 2014; Powroznyk et al., 2000; Aronson et al., 2008; Levy
et al., 2007; Cleviprex (clevidipine butyrate) injectable emulsion for
intravenous use [package insert], 2008). In 2014, Peacock et al. published
the results of a randomized, open-label active control study (PRONTO)
evaluating the efﬁcacy of clevidipine versus standard of care (SOC)
anti-hypertensive therapy and concluded that clevidipinewas responsi-
ble for a rapid reduction in blood pressure and dyspnea improvement in
hypertensive AHF patients (Peacock et al., 2010).
Calcium inﬂux during depolarization in vascular smooth muscle
(VSM) is prevented by clevidipine administration, blocking intracellular
phosphodiesterase with an increase in guanosinemonophosphate. This
mechanism is responsible for an inhibition in VSMcontractility associat-
ed with cardiopulmonary and systemic vasodilation (Murphy and
Brower, 2011). A reverse translational medicine approach was used by
Dahl et al. (2016) in order to test the idea that, in human lungs, a unique
combination of Cav1.2 splice variants is expressed with a higher afﬁnity
for clevidipine than the same splice variant in other tissue. The authors
reﬁne the general understanding of how pannexin-1 (Panx1), known to
act as a major adenosine triphosphate (ATP) release channel, affects
Cav1.2 pharmacology and increases its afﬁnity for clevidipine. Further
research was encouraged in order to clarify the role of splice variantsom.2016.06.027.
Wexner Medical Center, N411
USA.
a).
ical Center. Published by Elsevier B.V.to the pathophysiology of AHF in the light of a new paradigm generated
by Panx1/Cav1.2 interaction (Dahl et al., 2016).
pharmacological proﬁle for clevidipine when compared to the same
variants expressed in other tissues. They also considered the hypothesis
that clevidipine-induced dyspnea relief is due to clevidipine acting on
Panx1 channels in lung tissue. The authors considered the possibility
that Panx1 associates with Cav1.2 in lung tissue, resulting in an
increased afﬁnity of Cav1.2 for clevidipine (Dahl et al., 2016).
Human lung tissue from eight donors “without overt disease, but
unsuitable for transplant” was provide by the Life Alliance Organ
Recovery Agency. cDNA was obtained from human lung parenchyma
and used to amplify regions of CACNA1C known to present splicing
variation. Eight splice variant combinations of CACNA1C exons
found in human lung tissue were tested. The effect of DHP
nicardipine on different Cav1.2 splice variants was tested as well.
The authors concluded that Cav1.2 splice variants with different
afﬁnities for clevidipine are identiﬁed in lung tissue and the higher
afﬁnity variants also present a selectively higher afﬁnity for different
DHPs (Dahl et al., 2016). The experiment found no direct effect of
clevidipine on Panx1 channels, known to mediate muscle relaxation
and contraction in VSM. However, the coexpression of Panx1 with
the high afﬁnity Cav1.2 splice variants showed a signiﬁcant reactivity
to lower clevidipine - but not nicardipine – concentrations.
The authors acknowledged the importance of previous research in
identifying the Cav1.2 splice variants altering DHP sensitivity (Dahl et
al., 2016). They established that “different splice variants of Cav1.2 confer
differences in the speciﬁcity of different DHPs”. Further research should
clarify the coexpression of Panx1/Cav1.2. Although some technical aspects
are questioned, such as the presence of mixed tissue in harvested donor
lungs (lung parenchyma, arterioles, venules) inﬂuencing the expression
pattern of the splice variants, new insights were provided in response to
previously unexplained clinical observations. An extensive body of
scientiﬁc evidence supports the fact that clevidipine is a superior drug
for treatment of acute hypertension, providing a rapid blood pressure
adjustment in the surgical and critical care setting, as demonstrated by
the ECLIPSE Trials (2008) (Aronson et al., 2008).This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
24 N. Stoicea et al. / EBioMedicine 10 (2016) 23–24The article published by Dahl et al. (2016) represents further progress
into elucidating clevidipine's effects on dyspnea in hypertensive AHF
patients, prompted by the well-known PRONTO pilot study.
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